Takeda Gains Approval for ADZYNMA® Intravenous Injection

Takeda Gains Approval for ADZYNMA® Intravenous Injection

By, Admin 28 March 2024

Takeda Receives Approval for ADZYNMA® Intravenous Injection 1500 in Japan to Treat Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Overview

Takeda (TSE: 4502/NYSE:TAK) has announced the approval of ADZYNMA (apadamtase alfa/cinaxadamtase alfa) by the Japanese Ministry of Health, Labour and Welfare for treating congenital thrombotic thrombocytopenic purpura (cTTP) in individuals aged 12 and above. cTTP, an extremely rare clotting disorder, results from a deficiency in the ADAMTS13 enzyme and can lead to severe complications if left untreated, with mortality rates exceeding 90% for acute events.

Significance of ADZYNMA

  • Yasushi Kajii, Head of R&D Japan Region at Takeda, emphasized the significance of this approval, marking a crucial advancement for cTTP patients in Japan who previously had limited treatment options. 
  • ADZYNMA, the first and only recombinant ADAMTS13 protein approved for cTTP, aims to address this unmet medical need by replacing the deficient enzyme.

Phase 3 Trial

  • The approval is based on comprehensive evidence from a Phase 3 trial (281102 NCT03393975), including data from Japanese patients, and is further supported by long-term safety and efficacy data from a continuation study (TAK-755-3002 NCT04683003). 
  • Notably, during the study, no acute TTP events occurred in patients receiving ADZYNMA prophylactic treatment, contrasting with one event in patients receiving plasma-based therapies.

Adverse Events

Regarding safety, the incidence of treatment-related adverse events was significantly lower in the ADZYNMA group compared to those receiving plasma-based therapy, indicating a favorable safety profile for ADZYNMA. Moreover, Takeda stated that this approval doesn't alter its fiscal forecast for the year ending March 31, 2024 (FY2023).

Approval and Other Info

  • ADZYNMA, also approved by the U.S. FDA, offers both prophylactic and on-demand treatment options for cTTP patients, providing flexibility in managing this debilitating condition. 
  • Its recommended dosage and administration have been outlined, catering to both prophylactic and acute treatment needs.

About CTTP

CTTP is a challenging condition associated with life-threatening complications and chronic symptoms. ADZYNMA's approval marks a significant step forward in addressing the unmet needs of cTTP patients, reflecting Takeda's commitment to advancing treatments for rare diseases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!